Entera Bio Ltd.ENTX
What Entera Bio Ltd. does.
Entera is a clinical stage company focused on developing first-in-class oral tablet formats of peptides or protein replacement therapies. We concentrate on underserved, chronic medical conditions for which oral administration of a protein therapy has the potential to significantly shift a treatment paradigm.
Currently, most protein therapies are administered via frequent intravenous, subcutaneous or intramuscular injections. In chronic diseases where patients require persistent management, these cumbersome, often painful and high-priced injections can create a major treatment gap. From a technical standpoint, oral delivery of peptides and therapeutic proteins is challenging due to the enzymatic degradation within the gastrointestinal tract and poor absorption into the blood stream. We leverage our N-Tab ® platform, which is designed to simultaneously stabilize large (4kD+) hydrophilic peptides in the gastrointestinal tract and promote their absorption into the bloodstream.
Our most advanced product candidate, EB613 (oral teriparatide, or oral PTH[1-34]), is being developed as the first oral, osteoanabolic (bone building) tablet treatment for osteoporosis. EB613 is being developed under a 505(b)(2) application to the listed drug, Forteo® (teriparatide SC injection, Eli Lilly), which was first approved by the FDA in 2002 for the treatment of postmenopausal women with osteoporosis at high risk of fracture and later indicated for men with osteoporosis and osteoporosis associated with sustained systemic glucocorticoid therapy. Forteo® has been in clinical use for over 20 years with a well-established benefit-risk profile.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $365,000 | $571,000 | $134,000 | $0 | $181,000 | $42,000 |
| Net income | -$11.2M | -$12.2M | -$13.1M | -$8.9M | -$9.5M | -$11.4M |
| Free cash flow | -$10.6M | -$9.1M | -$12.5M | -$7.3M | -$6.8M | -$7.5M |
More on ENTX.
- Entera Bio Ltd. summary
- Entera Bio Ltd. financial statements
- Entera Bio Ltd. key metrics
- Entera Bio Ltd. health scores and style box
- Entera Bio Ltd. earnings
- Entera Bio Ltd. dividends
- Entera Bio Ltd. valuation
- Entera Bio Ltd. ownership and insiders
- Entera Bio Ltd. peers
Figures from Entera Bio Ltd.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.